Lys287
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.1
Powered by Cell Signaling Technology
Home > Mono-methylation Site Page: > Lys287  -  PIK3C3 (human)

Site Information
GPsDHDLkPNAATRD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12262048
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 )
Disease tissue studied:
colorectal cancer ( 2 ) , colorectal carcinoma ( 2 ) , gastric cancer ( 15 ) , leukemia ( 2 ) , chronic myelogenous leukemia ( 2 ) , lung cancer ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , non-small cell lung cancer ( 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 ) , non-small cell lung adenocarcinoma ( 5 , 6 , 8 , 9 , 10 , 11 , 13 ) , non-small cell large cell lung carcinoma ( 6 , 9 ) , non-small cell squamous cell lung carcinoma ( 8 , 17 ) , small-cell lung cancer ( 3 , 4 )
Relevant cell line - cell type - tissue:

References 

1

Olsen JB, et al. (2016) Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics. Mol Cell Proteomics 15, 892-905
26750096   Curated Info

2

Wu Z, et al. (2015) A chemical proteomics approach for global analysis of lysine monomethylome profiling. Mol Cell Proteomics 14, 329-39
25505155   Curated Info

3

Rikova K (2013) CST Curation Set: 20125; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

4

Rikova K (2013) CST Curation Set: 20126; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

5

Rikova K (2013) CST Curation Set: 20127; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

6

Rikova K (2013) CST Curation Set: 20128; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

7

Rikova K (2013) CST Curation Set: 20129; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

8

Rikova K (2013) CST Curation Set: 20130; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

9

Rikova K (2013) CST Curation Set: 20131; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

10

Rikova K (2013) CST Curation Set: 20132; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

11

Rikova K (2013) CST Curation Set: 20133; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

12

Rikova K (2013) CST Curation Set: 18853; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

13

Rikova K (2013) CST Curation Set: 18852; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

14

Rikova K (2012) CST Curation Set: 16504; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

15

Rikova K (2012) CST Curation Set: 16501; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

16

Rikova K (2012) CST Curation Set: 16502; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

17

Rikova K (2012) CST Curation Set: 16503; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info

18

Possemato A (2009) CST Curation Set: 8360; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info